文献速递类风湿关节炎

类风湿关节炎患者使用改善病情抗风湿药治疗的缓解、应答、留存和持续用药:瑞典、丹麦和挪威协调队列研究

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts.
PubMed 文献 · RMD Open · 2023-01-01

该研究基于瑞典、丹麦和挪威八个大型类风湿关节炎临床登记数据库及一项实用性试验,制定协调研究方案,定义甲氨蝶呤单药、肿瘤坏死因子抑制剂和利妥昔单抗三类治疗队列,分析36个月随访期间缓解、应答、留存和持续用药等结局。结果显示队列规模约50至22000例,各结局比例随指标不同而有小到中度差异,1年留存和持续用药率>50%,但起始甲氨蝶呤或TNFi者<33%、起始利妥昔单抗者仅10%在1年时未加用其他DMARD且达到ACR/EULAR或SDAI缓解。

要点

  • 八个类风湿关节炎登记数据库和一项实用性试验的数据可协调分析,不损害内部效度或外推性。
  • 1年留存和持续用药率>50%,但起始甲氨蝶呤或TNFi者<33%在1年时未加其他DMARD且达缓解。
  • 起始利妥昔单抗者仅10%在1年时未加其他DMARD且达ACR/EULAR或SDAI缓解。

核心结论

  • 不同类风湿关节炎数据来源的数据协调可在不损害内部效度或外推性的情况下实现。
  • 达到缓解的比例低,提示类风湿关节炎治疗优化存在未满足需求。

研究设计与样本

  • 研究使用瑞典、丹麦和挪威八个大型类风湿关节炎临床登记数据库及一项实用性试验的数据。
  • 研究定义甲氨蝶呤单药(作为首个DMARD)、肿瘤坏死因子抑制剂(作为首个生物DMARD)和利妥昔单抗三类治疗队列。
  • 研究制定协调研究方案,定义36个月随访期间的时间点,收集治疗应答、留存、持续用药和六种替代缓解定义的临床访视数据。

主要发现

  • 队列规模范围约50至22000例类风湿关节炎患者。
  • 达到各结局的比例随结局指标不同而变化,但在队列内和队列间、国家间及治疗间的变异为小到中度。
  • 1年时留存和持续用药率>50%。
  • 起始甲氨蝶呤或TNFi的患者中<33%在1年时未加用其他DMARD且达到ACR/EULAR或SDAI缓解。
  • 起始利妥昔单抗的患者中仅10%在1年时未加用其他DMARD且达到ACR/EULAR或SDAI缓解。

关键数值与推荐

  • 研究采用六种替代缓解定义,包括ACR/EULAR和SDAI缓解。
  • 研究评估36个月随访期间的结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Precision medicine in rheumatoid arthritis (RA) requires a good understanding of treatment outcomes and often collaborative efforts that call for data harmonisation. We aimed to describe how harmonisation across study cohorts can be achieved and investigate how the observed proportions reaching remission vary across remission criteria, study types, disease-modifying antirheumatic drugs (DMARDs) and countries, and how they relate to other treatment outcomes. METHODS: We used data from eight existing large-scale, clinical RA registers and a pragmatic trial from Sweden, Denmark and Norway. In these, we defined three types of treatment cohorts; methotrexate monotherapy (as first DMARD), tumour necrosis factor inhibitors (TNFi) (as first biological DMARD) and rituximab. We developed a harmonised study protocol defining time points during 36 months of follow-up, collected clinical visit data on treatment response, retention, persistence and six alternative definitions of remission, and investigated how these outcomes differed within and between cohorts, by treatment. RESULTS: Cohort sizes ranged from ~50 to 22 000 patients with RA. The proportions reaching each outcome varied across outcome metric, but with small to modest variations within and between cohorts, countries and treatment. Retention and persistence rates were high (>50% at 1 year), yet <33% of patients starting methotrexate or TNFi, and only 10% starting rituximab, remained on drug without other DMARDs added and achieved American Congress of Rheumatology/European Alliance of Associations for Rheumatology or Simplified Disease Activity Index remission at 1 year. CONCLUSION: Harmonisation of data from different RA data sources can be achieved without compromising internal validity or generalisability. The low proportions reaching remission, point to an unmet need for treatment optimisation in RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Westerlind H, Glintborg B, Hammer HB, et al. Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts. RMD Open. 2023. PMID: 37673441. doi:10.1136/rmdopen-2023-003027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。